Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Nano Mobile Healthcare Inc. (VNTH)

Add VNTH Price Alert      Hide Sticky   Hide Intro
Moderator: kzivann, imgoingfishing1, ThoughtPower, OneBrokeMama, GC Investments
Search This Board: 
Last Post: 9/21/2017 3:28:16 PM - Followers: 196 - Board type: Free - Posts Today: 3

Partnernering with:


We are developing detection devices based on patented technology invented by the National Aeronautics and Space Administration (“NASA”) that was licensed to Nanobeak, and further sublicensed to us.

Effective as of February 20, 2014, our majority shareholder sublicensed to the Company rights acquired under a license agreement with the National Aeronautics and Space Administration (“NASA”) to certain inventions and patent rights owned by NASA relating to chemical sensing nanotechnology, for use within the United States and its territories. As a result of the sublicense, the Company is now a mobile health technology company that is developing personalized and point-of-care screening using applications based upon chemical sensing methods.
Our sublicense for the use of NASA technology has been extended by three years such that the exclusivity of the underlying patents now ends in 2021, providing us with the additional time we need to advance the healthcare applications when the law enforcement breathalyzer enters the marketplace. 



Nano Mobile Healthcare Inc.
Nano Mobile Healthcare (SEC name)  Vantage mHealthcare (ref. VNTH)

Business Description

Nano Mobile Healthcare - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a Bluetooth device that works with any smartphone, tablet or laptop. With its foundations in advanced nanotechnology, the Company's first product, the Nano Mobile Health Sensor, which is in development, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The Company has offices in New York City and Mountain View, CA. For more information, please visit us at




Before the Vantage Sensor, NASA used the sensor technology to protect the astronauts from harmful gases.

The NASA sensor technology offers nine years of results on the Space Shuttle and the International Space Station.

"The sensor was Awarded the NASA Invention of the Year "


'NANOBEAK Mobile (Stage 1 lung cancer detection) is the first sensor and app planned to be released in 2018.' - John Groman


UPDATE :  Thu 4/20/2017 3:04 PM

"we are working diligently to get our filings current, as well as to move forward with news"  VNTH President J. Peters
(via an investor's email inquiry & quoted response)


UPDATE :  Friday, 05/26/17 09:36:39 AM

"just as we worked to get the recent 10K filed, we are working diligently to catch-up on all our filings"
J. Peters
(via an investor's email inquiry & quoted response)


NanoBeak Development <>  Team


Age: 58

Education: West Scranton High School, 1975; bachelor’s degree, criminal justice, King’s College, 1979; juris doctor, Dickinson School of Law, 1983

Experience: Scranton police officer, 1978-1981; assistant, deputy and executive deputy attorney general with focus on organized crime and drugs, including as director of the Bureau of Narcotics Investigation, attorney general’s office, 1982-1998; director, federal high-intensity drug-tracking area, Philadelphia, 1998-1999; director, all federal high-intensity drug-trafficking areas, national drug czar’s office, 1999-2003; counterterrorism consultant, 2004-present; president and chief executive officer, Nano Mobile Healthcare Inc., 2014-present; president, MSGI Technology Solutions, Inc. (formerly, MSGI Security Solutions, Inc., Media Services Group), 2004-present; executive director, Scranton Cultural Center, 2011-2013; state executive deputy attorney general in charge of communications, 2013-2014.

Board Members Included as of May 30th 2017:

Robert Chicoski. Since 2004 Mr. Chicoski has been the acting CFO for two Boston-based businesses providing contract CFO services for all accounting, finance, tax and bank financing matters as well as other strategic business and corporate matters. From June 2012 through April 2017, Mr. Chicoski was the controller, acting Chief Financial Officer and Private Investor Mentor for GVP Global Corp, a Boston private equity investment company.  Mr. Chicoski has been a Certified Public accountant since 1969. He was the founder, Treasurer and Chief Financial Officer of a start- up company, World Energy Solutions, that was previously listed on the Over the Counter Exchange as XWES and subsequently acquired by EnerNOC in 2015. Mr. Chicoski received a BS in Accounting from Bentley College of Accounting and Finance.

James C. Katzaroff was appointed to serve as a member of the Company’s board of directors. James C. Katzaroff. Mr.  Katzaroff is the founder of Advanced Medical Isotope Corp. (Symbol: ADMD) and was the Chief Executive Officer from 2007 through December 2016.  Mr. Katzaroff continues to serve as a director of ADMD.  ADMD is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non-resectable tumors.   Mr. Katzaroff holds a Bachelor’s Degree in Business Economics from the University of California, Santa Barbara and has completed advanced management courses at the University of Washington.



John Groman

CURRENT:   NANOBEAK Mobile (Stage 1 lung cancer detection) is the first sensor and app planned to be released in 2018.

John Groman's History Excerpt

Nanobeak History Summary

My (John Groman) latest venture is a private medical device company that has a non-invasive, sensor and app that will detect stage one lung cancer as well as other detections offered at the price of $1 per test (wholesale). The technology combines our exclusive NASA license of four issued patents and two pending patents with the biomarker research and human trial data from our medical partner Johns Hopkins along with our own proprietary IP. The Sensor and app provide results in real time and will work with all Smartphones, Tablets, Laptops and Desktops. 

Nanobeak, Inc, May 2013 - Present (4 years 1 month)
Bella Sante, Chairman & Founder  - December 1993 – Present (23 years 6 months)
Eames Capital Partners, LLC March 2013 – Present (4 years 3 months)
Epsilon - Co Founder and EVP November 1969 – January 2000 (30 years 3 months) Greater Boston Area Advertising and database marketing agency

Harvard Business School


Images and some literature is courtesy of



The Nano Mobile Sensor detects chemicals and Volatile Organic Compounds using Carbon Nanotubes.

The sensor was Awarded the NASA Invention of the Year :

    'NANOBEAK' Development Team

PARENT COMPANY: Vantage mHealthcare Inc. (VNTH)


NASA Technology Space Certification


Nano Mobile Healthcare is developing a sensor that will screen for the Volatile Organic Compound signatures in a person’s breath. Our device and application (working with any smart phone, laptop or tablet) will be able to identify the presence of lung cancer from a single exhalation. Results will be able to be viewed by patient and doctor in-the-moment and when treatment options are discussed. The Nano Mobile Sensor was developed to address one of the longest standing unmet medical needs today which involves early stage lung cancer detection and to do so in an affordable, non-invasive, safe and convenient way.

Imagine a World




Vantage Health News History

USA TODAY - The Future Of Health Care Is Social And Techie

ISSUU - Government Health Care United States Buyers Guide: Winter 2014

Meditek - Could A Smartphone Detect Lung Cancer?

Mobile Health News - Scripps To Test NASA-Developed, Smartphone-Enabled Lung Cancer Sensor

Strategic Partnerships

We have entered into a strategic partnership with Theranostics Laboratory, a translational research company, with offices in the USA and New Zealand. Theranostics Laboratory was founded at the Cleveland Clinic in 2010 and works on subcontracted research, in collaboration with the Auckland Bioengineering Institute (ABI), in New Zealand, and with NASA (via NASA Grant NCC 9-58).

The Auckland Bioengineering Institute is recognized as a world-leader in the field of personalized modeling and is part of the international Virtual Physiologic Human (VPH) project. The Institute has successfully commercialized numerous mHealth technologies, including wireless telemetry systems, wearable sensors and a needle-free injectable system into the US market.

The partnership between the Theranostics Laboratory and the Auckland Bioengineering Institute (ABI) is a strategic alliance for us through which the lab will act as principal investigators for us in the areas of mobile strep detection, mobile virus detection and other related areas including breath sample conditioning methodologies. The partnership gives us access to world-class expertise and skill in the field of personalized modeling..

We are working in conjunction with Nanobeak, LLC, a strategic partner, as well as NASA, to develop a mobile app to be used in connection with our sensor that will enable law enforcement to screen for marijuana use and deliver in-the-moment results to the officer’s smartphone, tablet or laptop in the field. Given the increase of marijuana legalization and decriminalization efforts by a growing number of states, we have made the development of a law enforcement sensor the short-term priority. There is a growing need on the part of law enforcement across the country for a portable sensor to detect marijuana abuse and impaired driving. We also plan to incorporate alcohol detection along with the marijuana sensing capability in one device so that law enforcement can have the capability to detect both alcohol (DUI breathalyzer) and marijuana abuse in a single device. The law enforcement device offers a quicker path to market based on reduced testing and regulatory requirements as compared to a medical diagnostic device.

Regulatory Approval

Our products as well as our research and development activities are regulated by numerous governmental authorities, principally the U.S Food and Drug Administration (FDA), as well as state and foreign regulatory agencies.

In the US, we believe that the medical diagnostic devices will be classified by the FDA as Class II medical devices and require clearance through a Form 510K. There can be no assurance that the FDA will provide marketing clearance for the device.

Manufacturing, Distribution, Sales

We intend to outsource manufacturing, distribution and sales but we have not entered into any definitive agreements for these functions.


We intend to compete with other detection devices by offering products that have enhanced value, ease of use, simple functionality, compatibility with various platforms, reliability, attractive price and are high in quality. The Company also believes its intellectual property provides an advantage over current competitors.

Disease Screening

There are a variety of methods to screen for the presence of disease. We are focused on non-invasive, point of care diagnostics.

Following years of research, a number of companies are now in prototype phase with devices that can test the chemical compounds in a person’s breath and identify the early stages of disease. Entry to this market is expected to continue and sharply rise as more prototypes emerge and begin to gain market entry with commercialized products. While companies in development tend to be small and privately owned, there has been entry by larger publicly owned companies that have greater financial reserves, distribution channels and more experience in commercialization. Acquisitions and collaborations by and companies seeking a competitive advantage also affect the competitive environment. This is a global market, evidenced by the emergence of companies bringing competitive solutions from different parts of the world.

New competitors may emerge and may develop products and capabilities which compete directly with our products. No assurance can be given that we will be successful in competing in the industries identified or in other industries that would benefit from our technology.

Customers for our medical diagnostic products is expected to include health care providers such as medical doctors, nurse practitioners and physician assistants.

Narcotics Screening

There are currently a variety of breathalyzer smartphone apps which essentially focus on alcohol detection. We are developing devices to distinguish between alcohol and narcotics and screen for a variety of narcotics both legal and illicit.

Making up the narcotic detection space are both domestic and international organizations that range from small, privately held companies to larger companies that include an array of diagnostic narcotics solutions. Although this market is more developed than disease detection, the space is dominated by a few key players making the possibility for new entrants feasible. Because toxicology screens are the most common type of narcotics testing products on the market, we believe that advanced technology that both detects and monitors discrete drug levels in an individual’s system through exhalation will cause this market to expand. The consumer market for mobile applications which provide detection and ongoing monitoring capabilities is anticipated to be significant.

Customers for our product will include the different areas of law enforcement as well as the different areas of professional and amateur sports. Corporations are also a target area for the narcotics screening technology.


We outsource all of our non-executive functions to Nanobeak, LLC. As of the date of this filing Nanobeak has 18 employees and consultants, both full and part time, most of which are shared with NASA and other contractors. The employees are not presently covered by any collective bargaining agreement.


Presentation: Thursday, May 18 – 10:35 AM – 10:45 AM:

3 Columbus Circle, 15th Floor, New York, NY 10019
Phone: (212) 520-4950 |
Category: Chemical Sensor Technology
Innovation: Nanobeak




Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VNTH News: Current Report Filing (8-k) 05/31/2017 12:38:02 PM
VNTH News: Annual Report (10-k) 05/05/2017 04:42:03 PM
#14138  Sticky Note gater 06/16/17 08:14:58 AM
#13939  Sticky Note $VNTH 122page SEC Filing (5/05/17)...not your average sub-penny. Dr G Bucks 05/30/17 08:05:55 PM
#14988   Indeed, indeed, and indeed. ThoughtPower 09/21/17 03:28:16 PM
#14987   The share structure is amazing, we haven't dropped GC Investments 09/21/17 12:46:28 PM
#14986   It is great that you are so positive. gater 09/21/17 11:44:01 AM
#14985   Don't worry, the reward will be well worth GC Investments 09/19/17 07:09:18 PM
#14984   This waiting is killing me. Go VNTH!!! Kubaska1214 09/19/17 03:54:22 PM
#14983   Come on 9s... she wants to pop ThoughtPower 09/18/17 03:47:33 PM
#14982   Looking good this week. Whose ready? ThoughtPower 09/18/17 12:57:17 AM
#14981   And I am as well. Almost going on a Loseitall80 09/17/17 12:16:28 AM
#14980   The product release would be for detecting drug kzivann 09/15/17 11:16:45 AM
#14979   Best guess based on original exclusive NASA technology license. cruzverde 09/15/17 11:06:05 AM
#14978   VNTH .. still holding strong here .. FLOPDROPROLL 09/15/17 11:01:38 AM
#14977   "They are still aiming to bring product to kzivann 09/15/17 10:52:13 AM
#14976   Just possible that Nano Mobile Health and Nanobeak cruzverde 09/15/17 10:38:19 AM
#14975   Yep let's hope we've got something coming this month ThoughtPower 09/12/17 10:58:44 AM
#14974   No clue. I've never gotten any responses gater 09/12/17 06:41:35 AM
#14973   A company could get their stock revoked, by sidedraft 09/12/17 01:46:42 AM
#14972   Yes, but it is in the 10-Q dated gater 09/11/17 03:14:35 PM
#14971   Well, it's in the 5/5/17 filing . Paulness 09/11/17 02:56:19 PM
#14969   Big day boys! Let's run it!!! ThoughtPower 09/11/17 12:46:04 PM
#14968   Referencing March 2016 not future action is my kzivann 09/11/17 09:09:13 AM
#14967   r u talkin,,,,about 01/08/2016 filing? imgoingfishing1 09/11/17 08:33:56 AM
#14966   My thought too ThoughtPower 09/11/17 08:24:16 AM
#14965   Paulness I thought that was in reference to gater 09/11/17 08:01:10 AM
#14964   10-to-1 reverse split yeah we haven't seen that before.... ShizlDizl 09/11/17 12:30:05 AM
#14963   We have been strategizing and outlining a plan Paulness 09/10/17 09:22:38 PM
#14962   Where what page... ThoughtPower 09/10/17 04:09:25 PM
#14961   I see the clinical trials as positive for kzivann 09/10/17 02:11:38 PM
#14960   Before we get excited about clinical trials for gater 09/10/17 11:20:09 AM
#14959   Clinical trial to detect stage 1 cancer .. kzivann 09/10/17 08:25:34 AM
#14958   John Hopkins doesn't accept a trial study without kzivann 09/10/17 08:18:16 AM
#14957   Nice to see statement that clinical trials would kzivann 09/10/17 08:11:39 AM
#14956   Clinical trials starting for detection of Stage 1 kzivann 09/10/17 08:05:01 AM
#14955   Study @ John Hopkins? Wow, top notch clinic S3lfMade 09/09/17 09:41:27 PM
#14954   Nice find. Confirms what was said in the Kubaska1214 09/09/17 09:06:57 PM
#14953 buy up B makemillions 09/09/17 08:39:42 PM
#14952 makemillions 09/09/17 08:38:12 PM
#14951   Looking for that 10 to 1 rs to Paulness 09/09/17 02:39:52 PM
#14950   Market makers and special interest groups. If you GC Investments 09/08/17 08:20:47 PM
#14949   Hey GC - Question Baconmaker 09/08/17 05:16:26 PM
#14948   Once it's dead again, then we will run GC Investments 09/08/17 03:03:04 PM
#14947   They are letting the hype die down and GC Investments 09/08/17 03:02:48 PM
#14945   Gater - Yeah, back down to 7 again Baconmaker 09/08/17 02:46:47 PM
#14941   Eh still here just waiting to get mote ThoughtPower 09/05/17 01:55:18 PM
#14939   Geez...there we go again backwards!! gater 09/05/17 10:23:31 AM
#14938   Hey Shizl – Good one... Baconmaker 09/04/17 05:10:58 PM
#14937   Anyone see the video below? Towards the end Kubaska1214 09/03/17 03:18:08 PM
#14936   Hey funny enough I have a friend of ShizlDizl 09/01/17 10:32:38 PM
#14935   Kzivann Thanks - Here's My Update Baconmaker 08/31/17 02:35:54 PM
#14934   Agree..VNTH has potential to be a big win .. kzivann 08/31/17 10:18:55 AM
#14933   Grabbed 1.05M, chart looks primed, great product/people involved. FrankWhite 08/31/17 10:00:01 AM